From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
3α-Hydroxysteroid Dehydrogenase, Microorganism (3α-HSD) is an enzyme encoded by the AKR1C4 gene, which can catalyze the conversion of 3-ketosteroids into 3α-hydroxy compounds. 3α-Hydroxysteroid dehydrogenase plays an important role in the inactivation of androgen DHT, and can convert DHT into 3α-androstanediol with weak androgen activity, which can be used in the research of hirsutism .
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .
Adrenosterone ((+)-Adrenosterone) is a competitive hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1) inhibitor.
Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass. Adrenosterone acts as a suppressor of metastatic progression of human cancer cells .
BI-135585 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 can be used for type 2 diabetes research .
Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity .
11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
Ursocholic acid, a bile acid found predominantly in bile of mammals, is transformed into deoxycholic acid by the intestinal microflora in mice. Ursodeoxycholic acid is an inhibitor of 7α-hydroxysteroid dehydrogenase and hepatocyte nuclear factor 1α .
Palbinone is a terpenoid isolated from the roots of Paeonia albiflora Pallas, potently inhibits 3α-hydroxysteroid dehydrogenase (3α-HSD), with an IC50 of 46 nM. Anti-inflammatory activity .
BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC50 of 3.0 nM .
Tetrahydrocortisol-d5 is the deuterium labeled Tetrahydrocortisol. Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity[1][2].
Vibralactone D (Compound 1) is a metabolite isolated and cultured from natural basidiomycetes Boreostereum vibrans. Vibralactone D shows weak inhibitory activity against isoenzymes of 11b-hydroxysteroid dehydrogenase (HSD) (IC50 85.7 μM).
HSD17B13-IN-24 (41) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-25 (43) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-34 (75) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-37 (78) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-62 (141) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-78 (22) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-58 (96) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-89 (206) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-85 (186) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-84 (182) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-90 (4) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
SKI2852 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50s of 1.6 nM and 2.9 nM against mHSD1 and hHSD1, respectively .
TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC50 of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors .
HSD17B13-IN-95 (1) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .
HSD17B13-IN-96 (3) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .
HSD17B13-IN-98 (5) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .
HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity .
HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC50 values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
11alpha-Hydroxyprogesterone is the analogue of 11beta-Hydroxyprogesterone (HY-N2337), and can be used as an experimental control. 11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
11β-HSD1-IN-6 is a an 11β-HSD-1 inhibitor. The 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs) mediate the interconversion of the glucocorticoid (GC) corticosterone or cortisol to an inactive form, 11-dehydrocorticosterone (11-DHC) or Cortisone, respectively .
(R)-BMS-816336 (Compound 6n-1) is a potent and orally active inhibitor of human, mouse and cynomolgus monkey 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC50s of 14.5 nM, 50.3 nM and 16 nM, respectively .
AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a Ki of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC50 of 10.1 nM in cell-based assays . AMG-221 can be used for the research of type 2 diabetes .
BMS-770767 is an 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor in type 2 diabetes. 11β-HSD1 is an important enzyme that is widely expressed in liver, adipose tissue and other tissues and plays an important role in metabolic diseases such as diabetes and obesity .
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-10 (Compound 464) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-10 can be used in the research of liver diseases .
HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-6(Compound 475) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-6can be used in the research of liver diseases .
HSD17B13-IN-13 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-13 can be used in the research of liver diseases, such as NAFLD .
HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-68 (Compound 16) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-68 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-72 (Compound 62) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-72 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-77 (Compound 808) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-77 can be used for research on liver diseases or metabolic disorders .
PF-915275 is a potent, selective and orally active human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor with a Ki of 2.3 nM and an EC50 of 15 nM (in HEK293 cells). The dose-dependent effect of PF-915275 on conversion of cortisone to cortisol in primary human and monkey hepatocytes, with an EC50 of 20 and 100 nM, respectively .
(Rac)-BMS-816336 (Compound 6n) is a racemate of BMS-816336. (Rac)-BMS-816336 is a potent inhibitor of human and mouse 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC50s of 10 nM and 68 nM, respectively. (Rac)-BMS-816336 has good metabolic stability .
HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research .
Diethylstilbestrol (Stilbestrol) is a non-steroidal female hormone that has oral activity and can act on menopausal and postmenopausal disorders. Diethylstilbestrol can induce DNA oxidation and Apoptosis of spermatogonial stem cells. Diethylstilbestrol can induce thymocyte Autophagy Diethylstilbestrol is a 11β-hydroxysteroid dehydrogenase 2 (HSD11B2) inhibitor. .
AZD8329 is a potent 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with an IC50 of 9 nM for human 11β-HSD1, displays excellent selectivity versus 11β-HSD2, 17β-HSD1 and 17β-HSD3 .
17β-HSD10-IN-1 (compound 9) is an orally active inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with blood-brain permeability. 17β-HSD10-IN-1 doesn't result additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects .
HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-42 (compound 10)? is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-42? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-30 (compound 64) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-30? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-35 (compound 76) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM? estradiol? as substrates. HSD17B13-IN-35? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-101 is a selective inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for Estradiol is <0.1 μM. HSD17B13-IN-101 can be used in the study of nonalcoholic fatty liver disease (NAFLD) (WO2023146897A1; compound 94) .
Steroid sulfatase/17β-HSD1-IN-1 is a potent steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor with an IC50 value of 28 nM for cellular human steroid sulfatase. Steroid sulfatase/17β-HSD1-IN-1 can be used to research estrogen-dependent diseases .
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research .
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-48 (Compound 12) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-48 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-79 (Compound 32) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-79 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-54 (Compound 158) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-54 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-55 (Compound 167) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-55 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-51 (Compound 82) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-51 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-56 (Compound 89) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-60 (Compound 126) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-60 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-61 (Compound 132) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-61 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-64 (Compound 143) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-64 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-71 (Compound 149) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-71 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-82 (Compound 156) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-82 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-83 (Compound 150) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-83 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC50 value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .
HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
ABT-384 is a potent, selective 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. ABT-384 exhibits high affinity (Ki 0.1-2.7 nM) against rodent, monkey, and human 11β-HSD1. ABT-384 blocks regeneration of active cortisol. ABT-384 can be used for the research of Alzheimer’s disease (AD) .
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
HSD17B13-IN-11 (Compound 2) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-11 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-12 (Compound 3) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. HSD17B13-IN-12 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-16 (compound 8) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-16? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-18 (compound 13) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-18? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-19 (compound 16) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-19? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-21 (compound 17) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-21? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-23 (compound 18) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-23? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-27 (compound 30) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and ?< 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-27? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-31 (compound 32) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-31? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
HSD17B13-IN-32(Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-32can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .
11-Beta-hydroxyandrostenedione-d4 is the deuterium labeled 11-Beta-hydroxyandrostenedione. 11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor[1][2].
11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor. As 4-androstenedione increases, measuring plasma 11-Beta-hydroxyandrostenedione can distinguish the adrenal or ovarian origin of hyperandrogenism .
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-91 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-91 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
11-Beta-hydroxyandrostenedione-d7 is the deuterium labeled 11-Beta-hydroxyandrostenedione. 11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor [1][2]
17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor,targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10),a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer .
Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-3 irreversibly inhibits hSTS activity with anIC50 value of 27 nM. Steroid sulfatase/17β-HSD1-IN-3 can be used in the study of endometriosis and other estrogen-dependent diseases .
Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity with anIC50 value of 63 nM. Steroid sulfatase/17β-HSD1-IN-4 can be used in the study of endometriosis and other estrogen-dependent diseases .
Steroid sulfatase/17β-HSD1-IN-5 is a irreversible inhibitor of steroid sulfatase (STS) .Steroid sulfatase/17β-HSD1-IN-5 is a reversible and selective inhibitor of 7β-hydroxysteroid dehydrogenase type1 (17β-HSD1), with IC50s of 43 nM and 6.2μM for 17β-HSD1 and 17β-HSD2, respectively. Steroid sulfatase/17β-HSD1-IN-5 can be used for metabolic disease (especially for endometriosis) research .
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
18β-Glycyrrhetyl-3-O-sulfate (Glycyrrhetic acid 3-O-(hydrogen sulfate)) is a potent type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) inhibitor with an IC50 of 0.10 µM using rat kidney microsome. 18β-Glycyrrhetyl-3-O-sulfate is the major metabolite of Glycyrrhetinic acid (GA). 18β-Glycyrrhetyl-3-O-sulfate is the substrate of organic anion transporter (OAT) 1 and OAT3. 18β-Glycyrrhetyl-3-O-sulfate has anti-inflammatory effects and has the potential for pseudohyperaldosteronism research .
Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].
N-((RS)-2-Hydroxy-propyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
LPPM-8 is a ligand of Med25 and an inhibitor of Med25 protein-protein interactions (PPIs). LPPM-8 engages Med25 through interaction with the H2 face of its Activator Interaction Domain and stabilizes full-length protein in the cellular proteome. LPPM-8 is an orthosteric inhibitor of H2-binding transcriptional activators (such as ATF6a). LPPM-8 can be used for studying Med25 and Mediator complex biology .
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC50 of 0.027 μM in 3T3-L1 adipocytes .
Adrenosterone ((+)-Adrenosterone) is a competitive hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1) inhibitor.
Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass. Adrenosterone acts as a suppressor of metastatic progression of human cancer cells .
Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity .
11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
Ursocholic acid, a bile acid found predominantly in bile of mammals, is transformed into deoxycholic acid by the intestinal microflora in mice. Ursodeoxycholic acid is an inhibitor of 7α-hydroxysteroid dehydrogenase and hepatocyte nuclear factor 1α .
Palbinone is a terpenoid isolated from the roots of Paeonia albiflora Pallas, potently inhibits 3α-hydroxysteroid dehydrogenase (3α-HSD), with an IC50 of 46 nM. Anti-inflammatory activity .
Vibralactone D (Compound 1) is a metabolite isolated and cultured from natural basidiomycetes Boreostereum vibrans. Vibralactone D shows weak inhibitory activity against isoenzymes of 11b-hydroxysteroid dehydrogenase (HSD) (IC50 85.7 μM).
17β-HSD10-IN-1 (compound 9) is an orally active inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with blood-brain permeability. 17β-HSD10-IN-1 doesn't result additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects .
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research .
11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor. As 4-androstenedione increases, measuring plasma 11-Beta-hydroxyandrostenedione can distinguish the adrenal or ovarian origin of hyperandrogenism .
17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor,targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10),a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer .
The SULT2A1 protein utilizes PAPS for critical sulfonation of steroids and bile acids in the liver and adrenal glands. Its multifunctional activity extends to a variety of compounds, enhancing its water solubility to facilitate renal excretion. SULT2A1 Protein, Human (His) is the recombinant human-derived SULT2A1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SULT2A1 Protein, Human (His) is 284 a.a., with molecular weight of 34-38 kDa.
The SULT2B1 protein uses PAPS to catalyze sulfate conjugation, mainly sulfating cholesterol, and shows significant activity on steroids such as pregnenolone and DHEA. It plays a crucial role in epidermal cholesterol metabolism, regulating epidermal proliferation and differentiation. SULT2B1 Protein, Human (311a.a, His) is the recombinant human-derived SULT2B1 protein, expressed by E. coli , with C-6*His labeled tag. The total length of SULT2B1 Protein, Human (311a.a, His) is 311 a.a., with molecular weight of ~35.0 kDa.
The COLAER_02088 Protein, acting as a 7beta-hydroxysteroid dehydrogenase, transforms 7-oxo-lithocholate into chemopreventive UDCA in the human colon, showcasing its role in bile acid metabolism. This enzyme also exhibits reversible reactions, oxidizing UDCA and utilizing NADPH as its preferred electron acceptor, influencing bile acid dynamics and potential therapeutic applications. COLAER_02088 Protein, Collinsella aerofaciens is the recombinant COLAER_02088 protein, expressed by E. coli , with tag free.
The COLAER_02088 Protein, acting as a 7beta-hydroxysteroid dehydrogenase, transforms 7-oxo-lithocholate into chemopreventive UDCA in the human colon, showcasing its role in bile acid metabolism. This enzyme also exhibits reversible reactions, oxidizing UDCA and utilizing NADPH as its preferred electron acceptor, influencing bile acid dynamics and potential therapeutic applications. COLAER_02088 Protein, Collinsella aerofaciens (GST) is the recombinant COLAER_02088 protein, expressed by E. coli , with N-GST labeled tag.
HSD17B13 Protein plays a pivotal role in hepatic lipid metabolism, actively contributing to the oxidation of diverse lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4. Demonstrating versatile catalytic activity in vitro, HSD17B13, notably, exhibits retinol/retinal dehydrogenase activity, emphasizing its potential impact on crucial pathways associated with lipid processing and metabolism. HSD17B13 Protein, Human (P.pastoris, His-Myc) is the recombinant human-derived HSD17B13 protein, expressed by P. pastoris , with N-His, C-Myc labeled tag. The total length of HSD17B13 Protein, Human (P.pastoris, His-Myc) is 281 a.a., with molecular weight of ~34.8 kDa.
HSD17B14 protein, with NAD-dependent 17-beta-hydroxysteroid dehydrogenase activity, converts oestradiol to oestrone. Its enzymatic activity extends to both oestradiol and 5-androstene-3-beta,17-beta-diol in vitro, although the physiological substrate remains unidentified. HSD17B14 Protein, Human (HEK293, His) is the recombinant human-derived HSD17B14 protein, expressed by HEK293 , with C-His labeled tag. The total length of HSD17B14 Protein, Human (HEK293, His) is 270 a.a., with molecular weight of ~29.8 KDa.
The proteins encoded by ED genes are involved in a variety of physiological processes. HSD11B1 Protein, Human (His-SUMO) is the recombinant human-derived HSD11B1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of HSD11B1 Protein, Human (His-SUMO) is 268 a.a., with molecular weight of ~45.5 kDa.
Tetrahydrocortisol-d5 is the deuterium labeled Tetrahydrocortisol. Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity[1][2].
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .
11-Beta-hydroxyandrostenedione-d4 is the deuterium labeled 11-Beta-hydroxyandrostenedione. 11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor[1][2].
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
11-Beta-hydroxyandrostenedione-d7 is the deuterium labeled 11-Beta-hydroxyandrostenedione. 11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor [1][2]
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].
HSD3B1 Antibody is an unconjugated, approximately 41 kDa, rabbit-derived, anti-HSD3B1 polyclonal antibody. HSD3B1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in mouse, rat, and predicted: human, dog, cow, horse background without labeling.